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Abstract 
Background & Aims: Direct-acting antiviral therapies (DAA) are an important tool for hepatitis C 
virus (HCV) elimination. However, reinfection among people who inject drugs (PWID) may hamper 
elimination targets. We therefore estimated HCV reinfection rates among DAA-treated individuals, 
including PWIDs. 
     
Methods: We analyzed data from the BC Hepatitis Testers Cohort which included ~1.7 million 
individuals screened for HCV in British Columbia, Canada. We followed HCV-infected individuals 
treated with DAAs who achieved a sustained virologic response (SVR) and had ≥1 subsequent HCV 
RNA measurement to April 22
nd
, 2018. Reinfection was defined as a positive RNA measurement after 
SVR. PWIDs were identified using a validated algorithm and classified based on recent (<3 years) or 
former (≥3 years before SVR) use. Crude reinfection rates per 100 person-years (PYs) were calculated. 
Poisson regression was used to model adjusted incidence rate ratios (IRRs) and 95% confidence 
intervals (CI). 
 
Results: Of 4,114 individuals who met inclusion, most were male (n=2,692, 65%), born before 1965 
(n=3,411, 83%) and were either recent (n=875, 21%) or former PWIDs (n=1,793, 44%). Opioid-agonist 
therapy (OAT) was observed in 19% of PWIDs. We identified 40 reinfections during 2,767 PYs. 
Reinfection rates were higher among recent (3.1/100 PYs; IRR: 6.7, 95% CI: 1.9, 23.5) and former 
PWIDs (1.4/100 PYs; IRR: 3.7, 95% CI: 1.1, 12.9) than non-PWIDs (0.3/100 PYs). Among recent 
PWIDs, reinfection rates were higher among individuals born after 1975 (10.2/100 PYs) and those with 
co-infected with HIV (5.7/100 PYs). Only one PWID receiving daily OAT developed reinfection. 
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Conclusions: Population-level reinfection rates remain elevated after DAA therapy among PWIDs 
because of ongoing exposure risk. Engagement of PWIDs in harm-reduction and support services is 
needed to prevent reinfections.  
 
Abstract word count: 275 words 
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Lay Summary: 
We estimated HCV reinfection rates after successful treatment with direct-acting antiviral therapies. 
Our findings showed that the risk of reinfection was highest among people with recent injection drug 
use. Among people who inject drugs, daily use of opioid-agonist therapy was associated with a lower 
risk of reinfection.    
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Highlights 
 DAA therapies are an important component of HCV elimination strategies.  
 Larger population-level reports of reinfection rates after DAA therapy are lacking. 
 HCV reinfection rates remain elevated among people who recently injected drugs. 
 Opioid-agonist therapy mitigates reinfection risk. 
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Background 
Chronic hepatitis C virus (HCV) is associated with substantial morbidity and mortality, with > 71 
million people infected worldwide in 2015 [1]. In 2013, an estimated 700,000 deaths globally were 
attributed to HCV-related liver disease sequelae, namely cirrhosis and hepatocellular carcinoma [2]. 
Mortality is expected to increase as many individuals infected with HCV decades ago are aging and at 
high risk of chronic liver disease [3, 4]. With the introduction of highly effective and well-tolerated, 
all-oral direct-acting antiviral (DAA) therapies to treat chronic HCV infection[5, 6], there has been 
renewed optimism regarding the ability to reduce the HCV disease burden and improve treatment 
outcomes in traditionally difficult to treat or cure populations. This includes those co-infected with 
HIV[7] as well as people who inject drugs (PWID) [8].  
 
However, as HCV infection does not result in sterilizing immunity, individuals with ongoing risk 
activities remain vulnerable to reinfection following cure of their initial infection [9]. Thus, reinfection 
after successful HCV treatment is an important public health issue and may impact efforts to control 
HCV transmission [10, 11].  PWIDs have been shown to be adherent to DAA treatments and can be 
effectively cured [12, 13]. However, concerns about reinfection risk impacts clinical decision-making 
regarding treatment of PWIDs[14, 15] who remain at risk of ongoing transmission. Although, 
reinfection is a major concern in the DAA era, estimates of reinfection rates have been limited to the 
interferon era where treatment was largely restricted to motivated patients who would most likely 
benefit from therapy and reinfection rates were low [16-20]. As DAAs have mitigated concerns related 
to compliance and adherence among PWIDs with ongoing injection behaviours, it has been postulated 
that reinfection rates with DAAs may be higher than during the interferon era [21]. However, 
population-level data on reinfection following successful DAA treatment is scarce [11].  
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The objective of the current study was to assess HCV reinfection rates in a population-based cohort of 
HCV-infected individuals who initiated all-oral DAA therapy in British Columbia (BC), Canada, with 
an emphasis on those identified as PWIDs.  
 
Materials and methods 
 
Study population 
 
BC is a Canadian province with 4.8 million inhabitants. All residents of BC are registered in the 
publicly funded Medical Services Plan that acts as a single-payer system and covers services provided 
by fee for service practitioners including general practices and private laboratories. In 2016, an 
estimated 55,000 individuals were infected with HCV. Until March 2017, public reimbursement for 
DAA treatment in BC was restricted to patients, including PWIDs, with at least moderate fibrosis 
(METAVIR stage ≥ F2). Between April 2017 and March 2018, access was expanded to include 
individuals with comorbidities such as HIV co-infection, diabetes, chronic kidney disease, or any other 
condition that could accelerate disease progression or necessitate early treatment [22]. Starting March 
2018, treatment is available to anyone with HCV with regardless of fibrosis level.  
 
We utilized data from the British Columbia Hepatitis Testers Cohort (BC-HTC) which includes all 
individuals tested for HCV or HIV at the British Columbia Centre for Disease Control Public Health 
Laboratory (BCCDC-PHL) or who have been reported to public health as a confirmed case of HCV, 
HIV, hepatitis B or active tuberculosis (Supplementary Table 1). Using a unique personal health 
number, these data were linked with data on medical visits, hospitalization records, prescription drug 
dispensations, and deaths. All dispensed medications including HCV treatments and opioid-agonist 
therapy (OAT) are recorded in a central system called PharmaNet, included in the cohort. The 
BCCDC-PHL is a centralized laboratory responsible for performing nearly all serologic testing (95%) 
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and all confirmatory HCV RNA testing and HCV genotype testing in BC. Further information about 
the BC-HTC, including methodology and data linkages have previously been published [23, 24].  
 
This analysis included all HCV-positive individuals successfully treated with an all-oral, interferon-
free, DAA regimen and who had at least one valid HCV RNA measurement after achieving a sustained 
virologic response (SVR, see Case definitions). DAA therapy became available in BC on January 23
rd
, 
2014. HCV RNA laboratory results were available until April 22
nd
, 2018. To allow sufficient follow-up 
time to observe reinfection events, we, therefore, included individuals who initiated treatment until July 
15
th
, 2017.  
 
Data linkage to establish the BC-HTC was performed under the auspices of the BCCDC’s public health 
mandate. This study was reviewed and approved by the Behavioral Research Ethics Board at the 
University of British Columbia (H14-01649). 
 
Case definitions 
 
SVR was assessed using the first available HCV RNA measurement obtained between a minimum of 
10 weeks to a maximum of 52 weeks after the end date of the last DAA prescription (i.e. SVR date). 
Individuals with a negative or undetectable HCV RNA test were considered to have achieved SVR. 
HCV RNA measurements were determined using the Abbott Real-Time Reverse Transcriptase 
polymerase chain reaction assay, with a lower limit of detection of 12 IU/mL. We selected a minimum 
of 10 weeks to define SVR because in the clinical setting, physician appointments are not always 
scheduled at exactly 12 weeks [25]. Only the first DAA treatment episode was considered in this 
analysis. Reinfection was defined as a single positive HCV RNA test measured after SVR. The date of 
reinfection was calculated as the midpoint between the last negative and first positive HCV RNA 
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measurement. Reinfections were considered to be persistent if they did not result in spontaneous 
clearance within six months of reinfection [18].       
 
We assessed the following factors and their association with the risk of HCV reinfection: age at 
treatment initiation, birth cohort, sex, year of HCV diagnosis, HIV co-infection, injection drug use, 
OAT use, problematic alcohol use, and major mental illness.  
 
Injection drug use, problematic alcohol use, and major mental illness were defined based on 
international classification of diseases (ICD) diagnostic or procedure codes, or fee item codes from a 
medical-services plan (medical visits), discharge abstract database (hospital admissions), or 
prescription database, as applicable (Supplementary Table 2). HIV diagnosis was based on serologic 
testing as per provincial guidelines, a record in the provincial HIV/AIDS reporting system, or three 
medical visits or an admission to hospital with a HIV-related diagnostic code. Assessment of OAT was 
based on the record of dispensed prescriptions in the centralized prescription database, PharmaNet, 
which records all prescriptions dispensed in the province. For the primary analysis, we utilized a more 
sensitive algorithm to identify PWIDs that included injection-related infections (>90% sensitivity) in 
addition to a medical visit or hospital admission for major drug-related diagnoses [26]. More specific 
algorithms to identify PWIDs were explored in sensitivity analyses. We further classified PWIDs based 
on when the latest definition-specific administrative record was observed. Individuals with major drug 
or injection-related diagnoses in the last three years prior to SVR were considered to be recent PWIDs 
and those with diagnoses more than three years prior were considered to be former PWIDs. OAT use 
was assessed only among former or recent PWIDs and was classified as daily (≥ 84 daily 
dispensations) or non-daily use (< 84 dispensations), in the 12 weeks prior to SVR. This time period 
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was selected to correspond to OAT use since the end of therapy. Presence or absence for all of these 
covariates were assessed prior to the SVR date. 
 
Statistical analysis 
We compared demographic and risk factor characteristics between included and excluded patients (i.e. 
those without post-SVR measurements) who achieved SVR. Included individuals were followed from 
the SVR date until reinfection or their last negative HCV RNA measurement. We calculated incidence 
rates per 100 person-years (PYs) of follow-up for overall and persistent HCV reinfections and 
corresponding 95% confidence intervals (CIs), assuming a Poisson distribution. Cumulative incidence 
curves compared the risk of reinfection by PWID status. Poisson regression was used to model both 
age and sex-adjusted incidence rate ratios (IRRs) as well as fully-adjusted IRRs for overall and 
persistent reinfection risk factors. All tests were two-sided at a significance level of 0.05. All analyses 
were performed using SAS version 9.4 (Cary, NC, USA). For further details regarding the materials 
used, please refer to the CTAT table. 
 
 
Results 
Between January 23rd, 2014 and July 15
th
, 2017, 5,292 individuals treated with all-oral DAA therapy 
achieved SVR. Of these individuals, 4,114 had at least one post-SVR HCV RNA measurement and 
were included in this analysis (Figure 1). Excluded individuals who also achieved SVR, but did not 
have a post-SVR HCV RNA measurement, were younger, more likely to be recent or former PWIDs or 
be on OAT, more likely to have a history of problematic alcohol consumption, and less likely to be 
HIV co-infected (Supplementary Table 3).  
 
Overall, most individuals were male (65%), Caucasian (92%), were between the ages of 45 and 64 
(median age 60 years, interquartile range [IQR]: 54, 64) and were PWIDs (65%), with either recent 
  
13 
 
(21%) or former history (44%) of injection (Table 1). Since completion of DAA therapy, OAT use was 
identified in 513 patients (19% of all PWIDs, n = 2,668). Individuals were treated predominately with 
sofosbuvir/ledipasvir (61%) or sofosbuvir plus ribavirin (17%) and the majority were HCV treatment-
naive (77%). Participants were followed for a total of 2,766.8 PYs. The median follow-up time was 123 
days (IQR: 84, 357) and the median time to the first post-SVR HCV RNA measurement was 86 days 
(IQR: 82, 106). Only 39% of participants had ≥ 2 post-SVR HCV RNA measurements. Among those 
testing more than once during study follow-up, the median time between HCV RNA measurements 
was 182 days (IQR: 90, 275).  
 
HCV reinfection  
During post-SVR follow-up, we identified 40 reinfections, of which 33 (83%) were persistent. Among 
the persistent reinfections, four were subsequently retreated and achieved SVR again. Comparison of 
pre-treatment and reinfection HCV genotypes are provided in Supplementary Table 4. The overall and 
persistent reinfection rates were 1.44 (95% CI: 1.03, 1.97) and 1.19 per 100 PYs (95% CI: 0.82, 1.68), 
respectively (Table 2). We observed higher overall and persistent reinfection rates among younger 
individuals (< 45 years), those born after 1975, males, recent PWIDs, and those with major mental 
illness, problematic alcohol consumption and HIV co-infection.  
 
Reinfections among PWID 
Among recent PWIDs, 21 reinfections were detected during 674.3 PYs of follow-up, yielding a 
reinfection rate of 3.11 per 100 PYs (95% CI: 1.93, 4.76). Of these, 18 were persistent reinfections 
(rate 2.67 per 100 PYs, 95% CI: 1.58, 4.22). Reinfection rates were highest among recent PWIDs born 
after 1975 (10.2 per 100 PYs, 95% CI: 3.74, 22.2; Table 3), those with HIV co-infection (5.67 per 100 
PYs, 95% CI: 2.59, 10.8) and those with problematic alcohol use (4.55 per 100 PYs, 95% CI: 2.35, 
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7.94). There was only one reinfection observed among PWIDs who used OAT daily in the previous 12 
weeks prior to SVR. Among recent PWIDs, the cumulative risk of both overall and persistent 
reinfection initially increased rapidly in the first 36 weeks after SVR, with reinfection being less 
common afterwards (Figure 2). The cumulative risk of reinfection at 52 weeks post-SVR was higher 
among recent PWIDs (2.8% overall and 2.3% for persistent reinfection), than among former (1.2% 
overall and 1.1% for persistent reinfection) or non-PWIDs (0.2% overall and 0.1% for persistent 
reinfection).  
 
Factors associated with reinfection  
In the multivariable Poisson model, PWIDs with recent (IRR 6.7, 95% CI: 1.9, 23.5) and former use 
(IRR 3.7, 95% CI: 1.1, 12.9) had a significantly elevated risk of overall reinfection (Table 4). Major 
mental health illness, problematic alcohol use, or HIV co-infection were not associated with HCV 
reinfection after SVR. Results were consistent when the analysis was restricted to persistent 
reinfections. In an analysis restricted to PWIDs, daily OAT use was associated with a non-significant 
reduction in the risk of reinfection (IRR 0.7, 95% CI: 0.1, 5.6).      
 
Sensitivity analyses 
Crude HCV reinfection rates were equally elevated among recent PWIDs regardless of the algorithm 
used to identify them (Supplementary Table 5). These rates ranged between 2.74 (95% CI: 1.63, 4.34) 
to 5.61 per 100 PYs (95% CI: 3.21, 9.11). Crude reinfection rates were highest among recent and 
former PWIDs identified using the most specific administrative database algorithm that required two 
medical services visits with only injection drug use-related codes. Results were also consistent with 
persistent HCV reinfection rates. In the multivariable Poisson model, recent PWIDs remained 
associated with overall reinfection, with IRRs ranging from 3.7 (95% CI: 1.5, 9.2) to 5.6 (95% CI: 2.3, 
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13.8). Model results were also consistent when persistent reinfections were examined (Supplementary 
Table 6) and when the main analysis was restricted to those who had SVR assessed  at least 12 weeks 
after treatment (Supplementary Table 7) .      
 
Discussion  
 
This paper reports the incidence of HCV reinfection in a large, real-world setting following the 
introduction of DAA therapies. To our knowledge, this is the first study of HCV reinfection post-DAA 
therapy in a representative and well-defined population. We found that the incidence of reinfection is 
higher among recent PWIDs and of note, those who used OAT continuously after completing HCV 
treatment, had a lower reinfection rate. These results highlight the need for engaging PWIDs with 
ongoing risk in harm reduction and prevention services following treatment to reduce reinfection risk to 
achieve World Health Organization (WHO) HCV elimination goals [27].  
 
There is limited data on HCV reinfection following successful HCV treatment with DAAs. An early 
meta-analysis of five studies, comprising 131 current or former PWIDs (range 9 to 42 participants) 
treated with interferon-based therapies, reported a pooled reinfection rate of 2.4 per 100 PYs [16]. 
More recently, a review of low and high-risk HCV mono-infected patients also treated primarily with 
interferon-based therapies, estimated reinfection rates of 0.19 and 2.2 per 100 PYs, respectively, 
although estimates in these studies ranged considerably [17]. Additional studies have reported 
interferon era reinfection rates that range between 4.9 and 15.5 per 100 PYs for those with ongoing 
injection exposure following treatment [18, 28, 29]. We recently reported reinfection rates of 1.00 and 
2.11 per 100 PYs, overall and for PWIDs, respectively, in BC, following successful interferon-based 
therapy [20]. Our current estimates of the reinfection rate following DAA therapies, overall (1.44 per 
100 PYs), and among recent PWIDs (3.11 per 100 PYs) is slightly higher than previous estimates from 
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the interferon era in the same population [20]. However, when we use the same PWID definition as the 
interferon analysis, we find that our reinfection estimate among recent PWIDs is considerably higher 
(4.99 per 100 PYs, Supplementary Table 5). In the interferon-era, PWIDs were less likely to be treated 
and those who were treated were likely not engaging in risky injecting behaviours, thus resulting in 
lower HCV reinfection rates [21, 24]. The introduction of all-oral DAA therapies have mitigated 
concerns related to HCV treatment duration and compliance, and have increased the number of current 
and former PWIDs who are eligible and willing to initiate treatment [30]. However, given the fibrosis 
restrictions in place in BC during the study period, our population likely represents one with more 
advanced liver disease and a relatively lower risk for HCV reacquisition. Thus, as treatment is 
expanded to everyone, including younger PWIDs with higher risk injecting behaviours, reinfection 
rates could likely increase.  
 
Other studies have reported higher HCV reinfection rates after DAA therapy among PWID and other 
high-risk populations, including men who have sex with men (MSM) [31, 32]. In a German population-
based registry of 2,074 DAA treated patients (37% PWIDs, 12% MSM), the overall reinfection rate 
was 1.8 per 100 PYs [31]. In an analysis of 199 current or former PWIDs enrolled in the C-EDGE Co-
Star trial, the reinfection rate was 2.3 per 100 PYs. As with the current study, more than 50% of 
reinfections occurred within one year of SVR in both of these settings. These data suggest that 
reinfection rates in our study are similar, though comparison is difficult due to differences in study 
populations and definitions.  
 
As expected, recent PWIDs had the highest reinfection rates. Among recent PWIDs, males, those with 
younger age, more recent HCV diagnosis, problematic alcohol use, and HIV co-infection had higher 
reinfection rates. Of note, there was only one reinfection identified among PWIDs engaged with OAT. 
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These findings confirm the need for harm-reduction and additional support strategies in reducing the 
risk of reinfection and the future liver disease burden among people with ongoing injecting behaviours 
with specific emphasis on younger, male PWIDs with problem alcohol use or HIV co-infection [33]. 
As with primary HCV infection, a myriad of single and multicomponent prevention strategies have 
been suggested to reduce ongoing exposure [10]. These include provision of OAT and high-coverage 
needle-syringe programs (NSP)[34], as well as psychotherapy and peer-based drug cessation programs 
for stimulant use [35]. In our previous study, we have shown significant effect of OAT and 
psychotherapy in reducing risk of reinfection among PWIDs treated with interferon [20]. Furthermore, 
additional strategies such as reducing stigma and discrimination associated with injecting behaviours, 
promotion of mental health services[20], linkages to social services improving food, housing and job 
security, may also reduce HCV reinfection following successful treatment [36]. As PWIDs with 
ongoing risk have multiple co-occurring conditions such as HIV co-infection, mental illness, and 
problematic alcohol use, integration of HCV care within multidisciplinary settings that offer both 
addiction, mental health and clinical and social work/services have been recommended [37]. With the 
ongoing opioid-related epidemic in North America, integrated services are expected to improve overall 
health and survival of PWIDs. 
 
This study utilized administrative-linked data to identify PWIDs with both recent and former injection 
exposure. Given the challenges associated with assessing substance and harm-related exposures using 
health services data, we employed a range of previously validated PWID definitions from the BC-HTC, 
however, it is unlikely that any approach would capture all injection drug users in the province [26]. 
Our primary analysis relied on a highly sensitive definition which included injection-related infections 
that would capture the most PWIDs in the province who would not be identified uniquely with major 
injectable drug or addiction-related diagnoses [38]. This provided a more conservative estimate of the 
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rate of HCV reinfection among PWIDs. Indeed, our alternative definitions that provided greater 
specificity, but lower sensitivity, yielded reinfection rates that were 80% higher among recent PWIDs. 
These findings suggest that HCV reinfection rates may be higher among those seeking care for specific 
drug or harm-related diagnoses and thus these individuals would benefit from interventions such as 
OAT and NSP that could be provided or referred to at the point-of-care. Alternatively, however, it is 
possible that these individuals may be more closely monitored for reinfection, given their ongoing risk 
behaviours, and this is reflected in their higher reinfection rates.             
 
A major strength of the current study included the use of administrative-linked data which allowed us 
to capture all DAA treatment initiators, as well as OAT use, in a well-defined study population. 
Furthermore, given centralized HCV RNA testing at BCCDC-PHL, the frequency and timing of RNA 
measurements reflects the real-world clinical management of HCV-infected individuals post-SVR. This 
has resulted in increased generalizability of our findings to other jurisdictions in Canada and abroad. 
Lastly, to date, this is the largest and only population-based study of HCV reinfection rates after SVR 
with all-oral, interferon-free therapies [11]. Using linked laboratory and administrative data has 
provided a strong foundation for population-level monitoring of HCV reinfection rates, which will help 
support the program planning required to achieve WHO HCV elimination goals. This framework also 
demonstrates a proof of concept that could be applied in other settings with similar population-based 
data sources for monitoring reinfection rates in the entire population.   
 
The results from this study should be interpreted cautiously in light of several limitations. First, we 
could not distinguish late relapse from true reinfection which would require sensitive sequencing 
methods or phylogenetic analyses data [39]. However, a study of trial populations demonstrated that  
<3% of all episodes of sequencing-confirmed late relapse occurred after 12 weeks post-treatment [40]. 
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Based on these data it is probable that the recurrences of HCV RNA identified in this study are 
reinfections. This is also consistent with the fact that we found larger relative rates for HCV RNA 
recurrence among PWIDs with recent risks lends further credence these being reinfections as opposed 
to relapses [11].     
 
Second, post-SVR follow-up after DAA therapy is limited. As a result, it is unclear if or how 
reinfection rates will change with further time since achieving SVR. It is conceivable that those who 
have the greatest probability of engaging in high-risk behaviour would become reinfected soon after 
SVR, and thus reinfection rates would decrease with time. It is also possible that risk factors are 
variable and high rates of reinfection may persist many years after SVR [19]. In addition, it is also 
important to note that we may have underestimated reinfection rates given that we excluded patients 
without subsequent HCV RNA measurements who were more likely to be younger, male and recent 
PWIDs. This highlights the need for continued engagement of treated HCV patients in clinical care to 
identify possible reinfection episodes.   
 
Furthermore, although the median time to the first HCV RNA measurement after SVR was short, 
subsequent testing occurred approximately every six months, and thus it is possible that we may have 
underestimated the true incidence rate of reinfection following SVR given that we may have missed 
cases of spontaneous clearance after reinfection [41]. Recent evidence has suggested higher rates of 
spontaneous clearance among PWIDs who are repeatedly exposed to infections [42]. From a clinical 
standpoint, however, persistent reinfections are most relevant and, as others, we have attempted to 
characterize these reinfections separately from those that also spontaneous clear [18, 32]. Additionally, 
we may also have underestimated reinfection rates as we only included individuals who achieved SVR 
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and did not assess if those who we believe failed treatment were, in fact, quickly reinfected after end of 
treatment.   
 
The results from this study have important implications for the management of HCV-infected 
individuals undergoing DAA therapy. With the lifting of fibrosis-related treatment restrictions in 
Canada in 2018 and the greater emphasis on treatment-as-prevention as a strategy for HCV elimination, 
a greater number of PWIDs will be receiving DAAs. This will result in treatment of younger PWID, 
many of whom will continue to be exposed to HCV through ongoing substance use and high-risk 
behaviours. Therefore it is imperative to minimize the risk of reinfection. Our data suggest that 
engagement into OAT reduces reinfection risk and this likely needs to be part of a comprehensive harm 
reduction programs that are offered with DAA therapies.  
 
In conclusion, this is the first population-based study to address HCV reinfection in the DAA era and 
employed administrative-data linkages with near complete coverage to assess risk factors for HCV 
reinfection. We found that rates of HCV reinfection following successful treatment with DAA therapies 
are high among people with recent injection drug use exposure. Only one of the PWIDs who were on 
daily OAT developed reinfection, suggesting benefits of engagement in this strategy, although this 
requires further follow-up and a larger sample size to assess the long-term impact of OAT. Our results 
highlight the need for engagement of people with ongoing injecting risk in harm-reduction and support 
services to prevent reinfections following successful treatment. This population-level linked laboratory 
and administrative dataset provides a platform for comprehensive outcome evaluation during the DAA 
era. 
     
  
  
21 
 
Acknowledgements 
We acknowledge the assistance of BCCDC, PHSA Performance Measurement and Reporting, 
Information Analysts, Ministry of Health Data Access, Research and Stewardship, MSP, DAD, 
Medical Beneficiary and Pharmaceutical Services program areas, BC Ministry of Health, BC Cancer 
Agency and their staff involved in data access, procurement and data management. 
Disclaimer 
All inferences, opinions, and conclusions drawn in this manuscript are those of the authors, and do not 
reflect the opinions or policies of the Data Steward(s).  
  
22 
 
References 
Author names in bold designated shared co-first authorship. 
[1] Polaris Observatory. Global prevalence and genotype distribution of hepatitis C virus infection 
in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017;2:161-176. 
[2] Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 
causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 
2015;385:117-171. 
[3] Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat 
Rev Gastroenterol Hepatol 2013;10:553-562. 
[4] Thrift AP, El-Serag HB, Kanwal F. Global epidemiology and burden of HCV infection and 
HCV-related disease. Nat Rev Gastroenterol Hepatol 2017;14:122-132. 
[5] Dore GJ, Feld JJ. Hepatitis C virus therapeutic development: in pursuit of "perfectovir". Clin 
Infect Dis 2015;60:1829-1836. 
[6] Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral 
direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med 
2017;166:637-648. 
[7] Sikavi C, Chen PH, Lee AD, Saab EG, Choi G, Saab S. Hepatitis C and human 
immunodeficiency virus co-infection in the era of direct-acting antiviral agents: no longer a difficult to 
treat population. Hepatology 2018;67:847-857. 
[8] Grebely J, Bruneau J, Bruggmann P, Harris M, Hickman M, Rhodes T, et al. Elimination of 
hepatitis C virus infection among PWID: the beginning of a new era of interferon-free DAA therapy. 
Int J Drug Policy 2017;47:26-33. 
[9] Islam N, Krajden M, Shoveller J, Gustafson P, Gilbert M, Wong J, et al. Hepatitis C cross-
genotype immunity and implications for vaccine development. Sci Rep 2017;7:12326. 
  
23 
 
[10] Midgard H, Weir A, Palmateer N, Lo Re V, 3rd, Pineda JA, Macias J, et al. HCV epidemiology 
in high-risk groups and the risk of reinfection. J Hepatol 2016;65:S33-S45. 
[11] Falade-Nwulia O, Sulkowski M, Merkow A, Latkin C, Mehta SH. Understanding and 
addressing hepatitis C reinfection in the oral direct acting antiviral era. J Viral Hepat 2018;25:220-227. 
[12] Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, et al. Elbasvir-grazoprevir to 
treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial. Ann 
Intern Med 2016;165:625-634. 
[13] Grebely J, Dalgard O, Conway B, Cunningham EB, Bruggmann P, Hajarizadeh B, et al. 
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use 
(SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. Lancet Gastroenterol Hepatol 
2018;3:153-161. 
[14] Asher AK, Portillo CJ, Cooper BA, Dawson-Rose C, Vlahov D, Page KA. Clinicians' views of 
hepatitis C virus treatment candidacy with direct-acting antiviral regimens for people who inject drugs. 
Subst Use Misuse 2016;51:1218-1223. 
[15] Grebely J, Haire B, Taylor LE, Macneill P, Litwin AH, Swan T, et al. Excluding people who 
use drugs or alcohol from access to hepatitis C treatments - is this fair, given the available data? J 
Hepatol 2015;63:779-782. 
[16] Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, et al. Treatment of 
hepatitis C virus infection among people who are actively injecting drugs: a systematic review and 
meta-analysis. Clin Infect Dis 2013;57 Suppl 2:S80-89. 
[17] Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of late relapse or reinfection with 
hepatitis C virus after achieving a sustained virological response: a systematic review and meta-
analysis. Clin Infect Dis 2016;62:683-694. 
  
24 
 
[18] Midgard H, Bjoro B, Maeland A, Konopski Z, Kileng H, Damas JK, et al. Hepatitis C 
reinfection after sustained virological response. J Hepatol 2016;64:1020-1026. 
[19] Young J, Rossi C, Gill J, Walmsley S, Cooper C, Cox J, et al. Risk factors for hepatitis C virus 
reinfection after sustained virologic response in patients coinfected with HIV. Clin Infect Dis 
2017;64:1154-1162. 
[20] Islam N, Krajden M, Shoveller J, Gustafson P, Gilbert M, Buxton JA, et al. Incidence, risk 
factors, and prevention of hepatitis C reinfection: a population-based cohort study. Lancet 
Gastroenterol Hepatol 2017;2:200-210. 
[21] Ingiliz P, Rockstroh JK. Hepatitis C virus reinfection-more to come? Lancet Gastroenterol 
Hepatol 2017;2:150-151. 
[22] British Columbia Ministry of Health. PharmaCare coverage of new direct-acting antiviral drugs 
and expanded coverage for adults with chronic hepatitis C infection. 2017. 
https://www2.gov.bc.ca/assets/gov/health/health-drug-coverage/pharmacare/chc-new-daas-and-
expandedcoverage.pdf. Accessed June 1st, 2018. 
[23] Janjua NZ, Kuo M, Chong M, Yu A, Alvarez M, Cook D, et al. Assessing hepatitis C burden 
and treatment effectiveness through the British Columbia Hepatitis Testers Cohort (BC-HTC): design 
and characteristics of linked and unlinked participants. PLoS One 2016;11:e0150176. 
[24] Janjua NZ, Kuo M, Yu A, Alvarez M, Wong S, Cook D, et al. The population level cascade of 
care for hepatitis C in British Columbia, Canada: the BC Hepatitis Testers Cohort (BC-HTC). 
EBioMedicine 2016;12:189-195. 
[25] Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Real-world effectiveness of 
ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients. Hepatology 
2016;64:405-414. 
  
25 
 
[26] Janjua NZ, Islam N, Kuo M, Yu A, Wong S, Butt ZA, et al. Identifying injection drug use and 
estimating population size of people who inject drugs using healthcare administrative datasets. Int J 
Drug Policy 2018;55:31-39. 
[27] Grebely J, Dore GJ, Morin S, Rockstroh JK, Klein MB. Elimination of HCV as a public health 
concern among people who inject drugs by 2030 - what will it take to get there? J Int AIDS Soc 
2017;20:22146. 
[28] Weir A, McLeod A, Innes H, Valerio H, Aspinall EJ, Goldberg DJ, et al. Hepatitis C reinfection 
following treatment induced viral clearance among people who have injected drugs. Drug Alcohol 
Depend 2016;165:53-60. 
[29] Martinello M, Grebely J, Petoumenos K, Gane E, Hellard M, Shaw D, et al. HCV reinfection 
incidence among individuals treated for recent infection. J Viral Hepat 2017;24:359-370. 
[30] Janjua NZ, Islam N, Wong J, Yoshida EM, Ramji A, Samji H, et al. Shift in disparities in 
hepatitis C treatment from interferon to DAA era: a population-based cohort study. J Viral Hepat 
2017;24:624-630. 
[31] Ingiliz P, Wehmeyer M, Christensen S, Lutz T, Schewe K, Baumgarten A, et al. High incidence 
of HCV reinfection in MSM in the DAA era (CROI Abstract #612). 2018. 
[32] Dore GJ, Grebely J, Altice F, Litwin AH, Dalgard O, Gane EJ, et al. Hepatitis C reinfection and 
injecting risk behavior following Elbasvir/Grazoprevir treatment in participants on opiate agonist 
therapy: Co-Star Part B (Abstract AASLD 195). 2017. 
[33] Larney S, Peacock A, Leung J, Colledge S, Hickman M, Vickerman P, et al. Global, regional, 
and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people 
who inject drugs: a systematic review. Lancet Glob Health 2017;5:e1208-e1220. 
  
26 
 
[34] Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, et al. Needle syringe programmes 
and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. 
Cochrane Database Syst Rev 2017;9:CD012021. 
[35] Westergaard RP, Hull SJ, Merkow A, Stephens LK, Hochstatter KR, Olson-Streed HK, et al. 
Computerized tailored interventions to enhance prevention and screening for hepatitis C virus among 
people who inject drugs: protocol for a randomized pilot study. JMIR Res Protoc 2016;5:e15. 
[36] Strike C, Rudzinski K, Patterson J, Millson M. Frequent food insecurity among injection drug 
users: correlates and concerns. BMC Public Health 2012;12:1058. 
[37] Bruggmann P, Litwin AH. Models of care for the management of hepatitis C virus among 
people who inject drugs: one size does not fit all. Clin Infect Dis 2013;57 Suppl 2:S56-61. 
[38] Larney S, Peacock A, Mathers BM, Hickman M, Degenhardt L. A systematic review of 
injecting-related injury and disease among people who inject drugs. Drug Alcohol Depend 
2017;171:39-49. 
[39] Jacka B, Applegate T, Poon AF, Raghwani J, Harrigan PR, DeBeck K, et al. Transmission of 
hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada. J 
Hepatol 2016;64:1247-1255. 
[40] Yoshida EM, Sulkowski MS, Gane EJ, Herring RW, Jr., Ratziu V, Ding X, et al. Concordance 
of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing 
regimens for hepatitis C virus. Hepatology 2015;61:41-45. 
[41] Vickerman P, Grebely J, Dore GJ, Sacks-Davis R, Page K, Thomas DL, et al. The more you 
look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and 
clearance and implications for future vaccine study design. J Infect Dis 2012;205:1342-1350. 
  
27 
 
[42] Sacks-Davis R, Grebely J, Dore GJ, Osburn W, Cox AL, Rice TM, et al. Hepatitis C Virus 
Reinfection and Spontaneous Clearance of Reinfection--the InC3 Study. J Infect Dis 2015;212:1407-
1419. 
 
  
  
28 
 
Table 1: Baseline characteristics of participants for the analysis of HCV reinfection in British 
Columbia, Canada (n = 4,114) 
 
 n (%) or  
median (IQR) 
Age group  
     < 45 years 294 (7%) 
     45 to 64 years 2,948 (72%) 
     ≥ 65 years 872 (21%) 
Median age (IQR), years 60 (54, 64) 
Birth cohort  
< 1965 3,411 (83%) 
1965 to 1974 487 (12%) 
≥ 1975 216 (5%) 
Year of HCV diagnosis  
1990-1997 1,099 (27%) 
1998-2004 1,337 (32%) 
≥ 2005 1,678 (41%) 
Male gender 2,692 (65%) 
PWIDs  
       Recent (< 3 years before SVR) 875 (21%) 
       Former (≥ 3 years before SVR) 1,793 (44%) 
       No 1,446 (35%) 
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OAT, in previous 12 weeks, among recent or former PWIDs 513 (19%) 
Any past major mental illness 1,245 (30%) 
Any previous problematic alcohol use 998 (24%) 
HIV co-infection 403 (10%) 
HCV treatment experienced 960 (23%) 
HCV treatment regimen  
     Sofosbuvir/ledipasvir  2,497 (61%) 
     Sofosbuvir plus ribavirin 696 (17%) 
     Sofosbuvir/velpatasvir  393 (9%) 
     Ombitasvir/paritaprevir/ritonavir plus dasabuvir 375 (9%) 
     Other 153 (4%) 
HCV genotype  
1 3,106 (75%) 
2 316 (8%) 
3 526 (13%) 
Mixed/Other 166 (4%) 
 
HCV, hepatitis C virus; IQR, interquartile range; OAT, opioid-agonist therapy; PWIDs, people who 
inject drugs; SVR, sustained virologic response. 
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Table 2: Crude HCV reinfection incidence rates, per 100 person-years, for overall and persistent 
HCV reinfection, after successful DAA therapy in British Columbia, Canada (n = 4,114) 
  All reinfections Persistent reinfections 
 Person-years N Rate  
(95% CI) * 
N Rate  
(95% CI) * 
Overall 2,766.80 40 1.44 (1.03, 1.97) 33 1.19 (0.82, 1.68) 
Age group      
     < 45 years 216.24 9 4.16 (1.90, 7.90) 9 4.16 (1.90, 7.90) 
     45 to 64 years 2,026.04 29 1.43 (0.96, 2.06) 23 1.14 (0.72, 1.70) 
     ≥ 65 years 524.52 2 0.38 (0.05, 1.38) 1 0.19 (0, 1.06) 
Birth cohort      
< 1965 2,263.34 25 1.10 (0.71, 1.63) 19 0.84 (0.51, 1.31) 
1965 to 1974 352.64 9 2.55 (1.17, 4.84) 8 2.27 (0.98, 4.47) 
≥ 1975 150.81 6 3.98 (1.46, 8.66) 6 3.98 (1.46, 8.66) 
Year of HCV diagnosis      
1990-1997 760.89 13 1.71 (0.91, 2.92) 9 1.18 (0.54, 2.25) 
1998-2004 921.25 17 1.85 (1.07, 2.95) 14 1.52 (0.83, 2.55) 
≥ 2005 1,084.43 10 0.92 (0.44, 1.70) 10 0.92 (0.44, 1.70) 
Gender      
Male 1,805.26 32 1.77 (1.21, 2.50) 28 1.55 (1.03, 2.24) 
Female 961.53 8 0.83 (0.36, 1.64) 5 0.52 (0.17, 1.21) 
PWID      
 Recent (< 3 years before 
SVR) 
674.28 21 3.11 (1.93, 4.76) 18 2.67 (1.58, 4.22) 
 Former (≥ 3 years before 
SVR) 
1,137.60 16 1.41 (0.80, 2.28) 13 1.14 (0.61, 1.95) 
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 No 954.91 3 0.31 (0.06, 0.92) 2 0.21 (0.03, 0.76) 
OAT, in previous 12 weeks, 
among recent or former PWIDs 
     
Daily use 52.59 1 1.90 (0.05, 10.6) 1 1.90 (0.05, 10.6) 
Non-daily use 292.62 12 4.10 (2.12, 7.16) 12 4.10 (2.12, 7.16) 
Any past major mental illness      
Yes 901.92 19 2.11 (1.27, 3.29) 16 1.77 (1.01, 2.88) 
No 1,864.87 21 1.13 (0.70, 1.72) 17 0.91 (0.53, 1.46) 
Any previous problematic 
alcohol use 
     
Yes 667.96 16 2.40 (1.37, 3.89) 13 1.95 (1.04, 3.33) 
No 2,098.84 24 1.14 (0.73, 1.70) 20 0.95 (0.58, 1.47) 
HIV Co-Infection      
Yes 378.44 13 3.44 (1.83, 5.87) 12 3.17 (1.64, 5.54) 
No 2,388.36 27 1.13 (0.75, 1.64) 21 0.88 (0.54, 1.34) 
 
* Rate per 100 person-years 
CI, confidence interval; HCV, hepatitis C virus; OAT, opioid agonist therapy; PWIDs, people who 
inject drugs; SVR, sustained virologic response. 
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Table 3: Crude HCV reinfection incidence rates and 95% confidence intervals, per 100 person-
years, for overall and persistent HCV reinfection among PWIDs (n = 2,668) * 
 All PWIDs (n = 2,668) Recent PWIDs (n = 875) Former PWIDs (n = 1,793) 
 All 
reinfections 
Persistent 
reinfections 
All 
reinfections 
Persistent 
reinfections 
All 
reinfections 
Persistent 
reinfections 
Age group       
     < 45 years 5.64  
(2.58, 10.7) 
5.64  
(2.58, 10.7) 
10.4  
(4.74, 19.7) 
10.4  
(4.74, 19.7) 
0  
(0, 5.07) 
0  
(0, 5.07) 
     45 to 64 
years 
2.00  
(1.32, 2.91) 
1.55  
(0.96, 2.38) 
2.26  
(1.17, 3.94) 
1.69  
(0.77, 3.21) 
1.83  
(1.02, 3.02) 
1.46  
(0.76, 2.56) 
     ≥ 65 years 0.33  
(0, 1.85) 
0.33  
(0, 1.85) 
0  
(0, 6.58) 
0  
(0, 6.58) 
0.41  
(0.01, 2.27) 
0.41  
(0.01, 2.27) 
Birth cohort       
< 1965 1.54  
(0.97, 2.34) 
1.19  
(0.69, 1.91) 
1.88  
(0.86, 3.58) 
1.47  
(0.59, 3.02) 
1.37  
(0.73, 2.35) 
1.06  
(0.51, 1.94) 
1965 to 1974 3.26  
(1.49, 6.19) 
2.90  
(1.25, 5.71) 
4.35  
(1.60, 9.47) 
3.63  
(1.18, 8.46) 
2.17  
(0.45, 6.34) 
2.17  
(0.45, 6.34) 
≥ 1975 5.42  
(1.99, 11.8) 
5.42  
(1.99, 11.8) 
10.2  
(3.74, 22.2) 
10.2  
(3.74, 22.2) 
0  
(0, 7.14) 
0  
(0, 7.14) 
Year of HCV 
diagnosis 
      
1990-1997 2.04  
(1.05, 3.56) 
1.36 
(0.59, 2.68) 
2.22 
(0.72, 5.18) 
1.78 
(0.48, 4.55) 
1.93 
(0.77, 3.97) 
1.10 
(0.30, 2.82) 
1998-2004 2.44 
(1.39, 3.96) 
2.13 
(1.17, 3.58) 
3.83  
(1.75, 7.27) 
2.98  
(1.20, 6.14) 
1.74 
(0.70, 3.58) 
1.74 
(0.70, 3.58) 
≥ 2005 1.59 1.59 3.57  3.57  0.54 0.54 
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(0.73, 3.01) (0.73, 3.01) (1.44, 7.35) (1.44, 7.35) (0.07, 1.95) (0.07, 1.95) 
Gender       
Male 2.49  
(1.68, 3.56) 
2.16  
(1.41, 3.17) 
3.82  
(2.23, 6.12) 
3.37  
(1.89, 5.57) 
1.71  
(0.91, 2.93) 
1.45  
(0.72, 2.59) 
Female 1.15  
(0.46, 2.37) 
0.82  
(0.27, 1.92) 
1.74  
(0.47, 4.46) 
1.31  
(0.27, 3.82) 
0.79  
(0.16, 2.31) 
0.53  
(0.06, 1.90) 
Any past 
major mental 
illness 
      
Yes 2.53 
(1.52, 3.95) 
2.13  
(1.22, 3.46) 
3.02  
(1.45, 5.56) 
3.02  
(1.45, 5.56) 
2.15  
(0.98, 4.07) 
1.43  
(0.52, 3.11) 
No 1.70  
(1.00, 2.68) 
1.41  
(0.79, 2.33) 
3.20  
(1.60, 5.73) 
2.33  
(1.01, 4.59) 
0.97  
(0.39, 2.01) 
0.97  
(0.39, 2.01) 
Any previous 
problematic 
alcohol use 
      
Yes 2.69  
(1.54, 4.37) 
2.19  
(1.17, 3.74) 
4.55  
(2.35, 7.94) 
3.41  
(1.56, 6.48) 
1.21  
(0.33, 3.10) 
1.21  
(0.33, 3.10) 
No 1.72  
(1.07, 2.63) 
1.48  
(0.88, 2.34) 
2.19  
(1.00, 4.16) 
2.19  
(1.00, 4.16) 
1.49  
(0.77, 2.60) 
1.11 
(0.51, 2.12) 
HIV Co-
Infection 
      
Yes 3.97 
(2.12, 6.80) 
3.67 
(1.90, 6.41) 
5.67 
(2.59, 10.8) 
5.04 
(2.18, 9.93) 
2.38 
(0.65, 6.08) 
2.38 
(0.65, 6.08) 
No 1.62 
(1.04, 2.41) 
1.28 
(0.77, 2.00) 
2.33 
(1.20, 4.07) 
1.94 
(0.93, 3.57) 
1.24 
(0.64, 2.16) 
0.93 
(0.42, 1.76) 
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* Rate per 100 person-years  
HCV, hepatitis C virus; OAT, opioid-agonist therapy; PWIDs, people who inject drugs. 
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Table 4: Incidence rate ratios (IRRs) from Poisson regression models for overall and persistent 
HCV reinfection in British Columbia, Canada 
 All reinfections Persistent reinfections 
 Age and sex-
adjusted IRR 
(95% CI) 
Fully adjusted 
IRR * (95% CI) 
Age and sex-
adjusted IRR 
(95% CI) 
Fully adjusted 
IRR * (95% CI) 
PWID     
 Recent (< 3 years 
before SVR) 
8.0 (2.4, 26.9) 6.7 (1.9, 23.5) 9.7 (2.2, 42.3) 8.1 (1.8, 36.9) 
 Former (≥ 3 years 
before SVR) 
4.1 (1.2, 14.2) 3.7 (1.1, 12.9) 5.0 (1.1, 22.0) 4.4 (1.0, 19.8) 
 No 1.0 (Reference) 1.0 (Reference) 1.0 (Reference) 1.0 (Reference) 
Any past major mental 
illness 
    
Yes 1.8 (0.9, 3.3) 1.1 (0.5, 2.1) 1.8 (0.9, 3.6) 1.1 (0.5, 2.3) 
No 1.0 (Reference) 1.0 (Reference) 1.0 (Reference) 1.0 (Reference) 
Any previous 
problematic alcohol 
use 
    
Yes 1.8 (1.0, 3.4) 1.2 (0.6, 2.4) 1.7 (0.9, 3.5) 1.1 (0.5, 2.4) 
No 1.0 (Reference) 1.0 (Reference) 1.0 (Reference) 1.0 (Reference) 
HIV Co-Infection     
Yes 2.1 (1.1, 4.2) 1.6 (0.8, 3.3) 2.3 (1.1, 4.9) 1.8 (0.8, 3.7) 
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No 1.0 (Reference) 1.0 (Reference) 1.0 (Reference) 1.0 (Reference) 
 
CI, confidence interval; IRR, incidence rate ratio; PWIDs, people who inject drugs; SVR, sustained 
virologic response. 
* Models adjusted for age, sex and all other predictors shown in the table. 
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Figure legends 
Fig. 1. Study participant selection flow chart. HCV, hepatitis C virus. 
Fig. 2. Cumulative incidence curves for reinfection, by injection drug use history. 
(A) All reinfections. Level of significance: p < 0.001 (Gray's K-Sample Test).  (B) Persistent 
reinfections. Level of significance: p < 0.001 (Gray's K-Sample Test). 
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Hepatitis C Virus Reinfection after Successful Treatment with Direct-Acting Antiviral Therapy 
in a Large Population-Based Cohort 
 
 
Highlights 
 DAA therapies are an important component of HCV elimination strategies.  
 Larger population-level reports of reinfection rates after DAA therapy are lacking. 
 HCV reinfection rates remain elevated among people who recently injected drugs. 
 Opioid-agonist therapy mitigates reinfection risk. 
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